Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Incyte Corp
(NQ:
INCY
)
57.10
+0.24 (+0.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Incyte Corp
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone
February 07, 2023
Haemonetics stock rose within a buy zone on Tuesday, but Incyte stock toppled.
Via
Investor's Business Daily
Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst
February 07, 2023
Via
Benzinga
Earnings Outlook For Incyte
February 06, 2023
Via
Benzinga
2 Steady Stocks to Buy in a Recession
February 03, 2023
Both companies are performing better than the broader market over the past year.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
January 31, 2023
Via
Benzinga
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
January 19, 2023
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before.
Via
Investor's Business Daily
Golden Cross Appears Before Incyte Investors
December 09, 2022
Via
Benzinga
Expert Ratings for Incyte
October 18, 2022
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings
September 29, 2022
Via
Benzinga
7 Biotech Stocks That Will Make You Rich in 10 Years
January 18, 2023
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.
Via
InvestorPlace
BriaCell Therapeutics' Mission: Destroy Breast & Prostate Cancers
January 18, 2023
From my analysis of BriaCell, it would make a great buy and hold investment. If, and when, it is bought out by a major pharmaceutical company, or brings a product directly to market itself, its stock...
Via
Talk Markets
Why These 7 Healthcare Stocks Could Soar in 2023
January 02, 2023
These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023.
Via
InvestorPlace
Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion
December 31, 2022
China Biopharma deal activity in 2022 was certainly slower than the previous year, but the ten largest deals, many of them booked in the second half of the year, totaled a decent $21.5 billion by...
Via
Talk Markets
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
December 29, 2022
These two biotechs are flying high right now.
Via
The Motley Fool
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
December 18, 2022
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years.
Via
InvestorPlace
Cramer Says He's 'Always Liked' This Drug Company
December 16, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Oshkosh Corporation (NYSE: OSK) is a "slow grower.
Via
Benzinga
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
December 13, 2022
Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX<
Via
Benzinga
7 Cash-Rich Stocks to Buy for Peace of Mind
November 04, 2022
It pays to hold cash-rich stocks that can weather any storm because of their financial strength. Investors may want to watch these seven.
Via
InvestorPlace
2 Biotech Stocks That Could Make You Richer
November 04, 2022
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.
Via
The Motley Fool
Recap: Incyte Q3 Earnings
November 01, 2022
Incyte (NASDAQ:INCY) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Incyte missed estimated earnings by...
Via
Benzinga
Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm'
October 17, 2022
Via
Benzinga
2 Cathie Wood Stocks That Are Beating the Market This Year
October 07, 2022
One is doing much better than the other year to date, but they both have solid prospects ahead.
Via
The Motley Fool
Incyte Acquires Villaris Therapeutics, Deepening Portfolio For Immune-Mediated Dermatologic Diseases
October 03, 2022
Via
Benzinga
Death Cross Looms Over Incyte Investors
September 22, 2022
If history is any guide, there may be trouble ahead for shares of Incyte (NASDAQ:INCY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Via
Benzinga
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
September 15, 2022
Via
Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
August 26, 2022
Via
Benzinga
Incyte Gets FDA Nod For Hematologic Malignancies Candidate
August 26, 2022
The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ: INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with...
Via
Benzinga
10 Most Oversold Stocks To Buy In August 2022
August 10, 2022
Looking for some oversold stocks to buy? Here's the 10 most oversold on the S&P 500 for August 2022.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
August 03, 2022
Via
Benzinga
Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled
August 02, 2022
Jakafi sales beat and the company raised its guidance. But another drug fell short.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.